Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 7/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042553 | 0.99 | ALDH1A1 (0.36) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042607 | 0.93 | ALDH1A1 (0.39) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042486 | 0.91 | KMT2A (0.39) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042597 | 0.90 | ALDH1A1 (0.39) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042484 | 0.89 | S1PR2 (0.42) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042579 | 0.89 | ALDH1A1 (0.34) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042532 | 0.89 | KMT2A (0.39) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042586 | 0.88 | KDM4E (0.39) | S1PR2S1PR1S1PR3LPAR2ALDH1A1 | |
| SCHEMBL15042524 | 0.87 | CHRM2 (0.40) | S1PR2S1PR1S1PR3LPAR2KDM4E | |
| SCHEMBL15042485 | 0.87 | SCN8A (0.43) | S1PR2S1PR1S1PR3LPAR2SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.